Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vectibix and Keytruda with Neoadjuvant Chemotherapy in TN-IBC
NCT05177796Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Pathological Complete Response at 1 year. Planned start Mar 2022; status: withdrawn.
02
Drugs
panitumumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05177796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177796.